SUPN Annual CFO
$111.08 M
-$5.74 M-4.91%
31 December 2023
Summary:
As of January 23, 2025, SUPN annual cash flow from operations is $111.08 million, with the most recent change of -$5.74 million (-4.91%) on December 31, 2023. During the last 3 years, it has fallen by -$27.31 million (-19.74%). SUPN annual CFO is now -22.39% below its all-time high of $143.13 million, reached on December 31, 2019.SUPN Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SUPN Quarterly CFO
$53.52 M
+$17.90 M+50.24%
30 September 2024
Summary:
As of January 23, 2025, SUPN quarterly cash flow from operations is $53.52 million, with the most recent change of +$17.90 million (+50.24%) on September 30, 2024. Over the past year, it has increased by +$17.64 million (+49.18%). SUPN quarterly CFO is now -41.80% below its all-time high of $91.95 million, reached on June 30, 2020.SUPN Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SUPN TTM CFO
$172.50 M
+$17.64 M+11.39%
30 September 2024
Summary:
As of January 23, 2025, SUPN TTM cash flow from operations is $172.50 million, with the most recent change of +$17.64 million (+11.39%) on September 30, 2024. Over the past year, it has increased by +$78.81 million (+84.12%). SUPN TTM CFO is now -5.38% below its all-time high of $182.32 million, reached on June 30, 2020.SUPN TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SUPN Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -4.9% | +49.2% | +84.1% |
| 3 y3 years | -19.7% | +49.2% | +84.1% |
| 5 y5 years | -13.9% | +49.2% | +84.1% |
SUPN Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -12.6% | at low | -24.8% | +383.6% | at high | +140.7% |
| 5 y | 5-year | -22.4% | at low | -41.8% | +383.6% | -5.4% | +140.7% |
| alltime | all time | -22.4% | +291.7% | -41.8% | +380.1% | -5.4% | +366.8% |
Supernus Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $53.52 M(+50.2%) | $172.50 M(+11.4%) |
| June 2024 | - | $35.62 M(-7.2%) | $154.86 M(+54.3%) |
| Mar 2024 | - | $38.40 M(-14.6%) | $100.36 M(-9.7%) |
| Dec 2023 | $111.08 M(-4.9%) | $44.96 M(+25.3%) | $111.08 M(+18.6%) |
| Sept 2023 | - | $35.88 M(-290.1%) | $93.69 M(+30.7%) |
| June 2023 | - | -$18.87 M(-138.4%) | $71.66 M(-55.7%) |
| Mar 2023 | - | $49.13 M(+78.2%) | $161.65 M(+38.4%) |
| Dec 2022 | $116.83 M(-8.1%) | $27.56 M(+99.1%) | $116.83 M(-15.4%) |
| Sept 2022 | - | $13.84 M(-80.5%) | $138.03 M(+14.9%) |
| June 2022 | - | $71.12 M(+1553.2%) | $120.07 M(+26.1%) |
| Mar 2022 | - | $4.30 M(-91.2%) | $95.23 M(-25.1%) |
| Dec 2021 | $127.13 M(-8.1%) | $48.76 M(-1286.4%) | $127.13 M(+15.3%) |
| Sept 2021 | - | -$4.11 M(-108.9%) | $110.30 M(-8.1%) |
| June 2021 | - | $46.27 M(+27.8%) | $120.01 M(-27.6%) |
| Mar 2021 | - | $36.20 M(+13.4%) | $165.68 M(+19.7%) |
| Dec 2020 | $138.40 M(-3.3%) | $31.93 M(+470.3%) | $138.40 M(-7.9%) |
| Sept 2020 | - | $5.60 M(-93.9%) | $150.26 M(-17.6%) |
| June 2020 | - | $91.95 M(+931.3%) | $182.32 M(+53.1%) |
| Mar 2020 | - | $8.92 M(-79.6%) | $119.05 M(-16.8%) |
| Dec 2019 | $143.13 M(+11.0%) | $43.79 M(+16.3%) | $143.13 M(+8.3%) |
| Sept 2019 | - | $37.66 M(+31.3%) | $132.19 M(-15.8%) |
| June 2019 | - | $28.69 M(-13.1%) | $156.98 M(+16.4%) |
| Mar 2019 | - | $32.99 M(+0.4%) | $134.85 M(+4.5%) |
| Dec 2018 | $128.99 M(+12.5%) | $32.85 M(-47.4%) | $128.99 M(-2.6%) |
| Sept 2018 | - | $62.45 M(+852.5%) | $132.47 M(+21.5%) |
| June 2018 | - | $6.56 M(-75.8%) | $109.03 M(-15.1%) |
| Mar 2018 | - | $27.13 M(-25.3%) | $128.41 M(+12.0%) |
| Dec 2017 | $114.64 M | $36.34 M(-6.8%) | $114.64 M(+11.0%) |
| Sept 2017 | - | $39.01 M(+50.4%) | $103.24 M(+11.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2017 | - | $25.94 M(+94.2%) | $92.48 M(+11.0%) |
| Mar 2017 | - | $13.36 M(-46.4%) | $83.31 M(+24.7%) |
| Dec 2016 | $66.81 M(+93.5%) | $24.94 M(-11.7%) | $66.81 M(+8.1%) |
| Sept 2016 | - | $28.24 M(+68.3%) | $61.80 M(+74.3%) |
| June 2016 | - | $16.78 M(-634.0%) | $35.45 M(+12.0%) |
| Mar 2016 | - | -$3.14 M(-115.8%) | $31.65 M(-8.3%) |
| Dec 2015 | $34.52 M(-240.9%) | $19.93 M(+957.1%) | $34.52 M(+65.5%) |
| Sept 2015 | - | $1.89 M(-85.5%) | $20.86 M(+46.3%) |
| June 2015 | - | $12.98 M(-4997.0%) | $14.26 M(-352.1%) |
| Mar 2015 | - | -$265.00 K(-104.2%) | -$5.66 M(-76.9%) |
| Dec 2014 | -$24.50 M(-57.7%) | $6.26 M(-232.9%) | -$24.50 M(-39.0%) |
| Sept 2014 | - | -$4.71 M(-32.1%) | -$40.18 M(-21.2%) |
| June 2014 | - | -$6.94 M(-63.7%) | -$51.02 M(-14.7%) |
| Mar 2014 | - | -$19.10 M(+102.8%) | -$59.83 M(+3.2%) |
| Dec 2013 | -$57.95 M(+22.8%) | -$9.42 M(-39.4%) | -$57.95 M(-10.4%) |
| Sept 2013 | - | -$15.55 M(-1.3%) | -$64.67 M(+7.0%) |
| June 2013 | - | -$15.76 M(-8.5%) | -$60.42 M(+11.2%) |
| Mar 2013 | - | -$17.22 M(+6.7%) | -$54.35 M(+15.2%) |
| Dec 2012 | -$47.20 M(+30.4%) | -$16.14 M(+42.8%) | -$47.20 M(+20.0%) |
| Sept 2012 | - | -$11.30 M(+16.6%) | -$39.32 M(+5.9%) |
| June 2012 | - | -$9.69 M(-3.8%) | -$37.12 M(+1.8%) |
| Mar 2012 | - | -$10.07 M(+21.9%) | -$36.45 M(+0.7%) |
| Dec 2011 | -$36.19 M(+11.2%) | -$8.26 M(-9.3%) | -$36.19 M(+29.6%) |
| Sept 2011 | - | -$9.10 M(+0.9%) | -$27.93 M(+48.4%) |
| June 2011 | - | -$9.02 M(-7.9%) | -$18.82 M(+92.1%) |
| Mar 2011 | - | -$9.80 M | -$9.80 M |
| Dec 2010 | -$32.54 M(-1335.5%) | - | - |
| Dec 2009 | $2.63 M(-108.9%) | - | - |
| Dec 2008 | -$29.65 M(+112.1%) | - | - |
| Dec 2007 | -$13.98 M | - | - |
FAQ
- What is Supernus Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals annual CFO year-on-year change?
- What is Supernus Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals quarterly CFO year-on-year change?
- What is Supernus Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals TTM CFO year-on-year change?
What is Supernus Pharmaceuticals annual cash flow from operations?
The current annual CFO of SUPN is $111.08 M
What is the all time high annual CFO for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high annual cash flow from operations is $143.13 M
What is Supernus Pharmaceuticals annual CFO year-on-year change?
Over the past year, SUPN annual cash flow from operations has changed by -$5.74 M (-4.91%)
What is Supernus Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of SUPN is $53.52 M
What is the all time high quarterly CFO for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high quarterly cash flow from operations is $91.95 M
What is Supernus Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, SUPN quarterly cash flow from operations has changed by +$17.64 M (+49.18%)
What is Supernus Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of SUPN is $172.50 M
What is the all time high TTM CFO for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high TTM cash flow from operations is $182.32 M
What is Supernus Pharmaceuticals TTM CFO year-on-year change?
Over the past year, SUPN TTM cash flow from operations has changed by +$78.81 M (+84.12%)